Nephrocare Healt

  • Market Cap: Small Cap
  • Industry: Healthcare Services
  • ISIN: INE428V01029
  • NSEID: NEPHROPLUS
  • BSEID: 544647
INR
694.20
4.2 (0.61%)
BSENSE

Aug 07, 03:30 PM

BSE+NSE Vol: 61.0 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationUpcoming Result: Nephrocare Healt will declare its result soon on 11 Aug 2026
stock-recommendationMojo Score Change: Nephrocare Healt has changed its score on 03 Aug 2026. Click here to unlock latest mojo score!
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

61.0 k (-48.56%) Volume

Shareholding (Jun 2026)

FII

8.78%

Held by 17 FIIs

DII

9.05%

Held by 8 DIIs

Promoter

63.85%

Why is Nephrocare Health Services Ltd falling/rising?

09-Aug-2026

As of 08-Aug, Nephrocare Health Services Ltd's stock price is rising to 694.20, reflecting a 0.61% increase. This upward trend is supported by strong financial results and significant year-to-date performance, despite concerns over declining investor participation.

As of 08-Aug, Nephrocare Health Services Ltd's stock price is rising, currently at 694.20, reflecting a change of 4.2 (0.61%) upward. This increase can be attributed to several factors. Over the past week, the stock has outperformed the benchmark Sensex, gaining 1.83% compared to the Sensex's 0.52%. Additionally, the stock has shown a significant year-to-date performance, with a remarkable increase of 47.94%, while the Sensex has declined by 7.89%.<BR><BR>Today's performance indicates a trend reversal, as the stock has gained after two consecutive days of decline. Furthermore, despite underperforming its sector by 0.29% today, the stock remains above its 20-day, 50-day, 100-day, and 200-day moving averages, which suggests a generally positive trend in its price movement.<BR><BR>The company also benefits from being net-debt free, which is a positive indicator for long-term growth. Recent financial results have shown strong performance, with net sales reaching a record high of Rs 164.33 crore and a significant operating profit to interest ratio of 17.39 times. However, it is important to note that there has been a decline in investor participation, with delivery volume falling by 27.5% against the 5-day average, and institutional investors reducing their stake by 0.75% over the previous quarter.<BR><BR>In summary, while there are some concerns regarding falling investor participation and high valuation metrics, the stock's recent upward movement is supported by strong financial results and overall positive performance relative to the market.

View full answer

Should I buy, sell or hold Nephrocare Health Services Ltd?

05-Aug-2026

What does Nephrocare Healt do?

11-Jun-2026

Nephrocare Health Services Ltd is a small-cap healthcare company that reported net sales of 266 Cr and a net profit of 30 Cr for March 2026. Key metrics include a P/E ratio of 93.00 and a market cap of INR 7,195 Cr.

Overview: <BR>Nephrocare Health Services Ltd operates in the healthcare services industry and is classified as a small-cap company.<BR><BR>History: <BR>The incorporation year is not provided, and there are no status changes mentioned. The latest quarterly results reported are for March 2026, showing net sales and profit.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 266 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 30 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 7,195 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 93.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.31 <BR>Return on Equity: 6.88% <BR>Price to Book: 6.47 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: Not available. <BR>Email: Not available. <BR>Website: Not available.

View full answer

How big is Nephrocare Healt?

11-Jun-2026

As of 10th June, Nephrocare Health Services Ltd has a market capitalization of 7,195.00 Cr, with net sales of 990.26 Cr and a net profit of 78.01 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Nephrocare Health Services Ltd has a market capitalization of 7,195.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 990.26 Cr, while the sum of Net Profit for the same period is 78.01 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 584.11 Cr, and Total Assets are valued at 975.89 Cr.

View full answer

Who are the peers of the Nephrocare Healt?

11-Jun-2026

Nephrocare Healt's peers include Poly Medicure, Vijaya Diagnost., Indegene, Metropolis Healt, Thyrocare Tech., Suven Life Scie., Vimta Labs, Krsnaa Diagnost., Suraksha Diagno., and Laxmi Dental. Thyrocare Tech. leads with a 1-year return of 61.22%, while Laxmi Dental has the lowest at -48.44%.

Peers: The peers of Nephrocare Healt are Poly Medicure, Vijaya Diagnost., Indegene, Metropolis Healt, Thyrocare Tech., Suven Life Scie., Vimta Labs, Krsnaa Diagnost., Suraksha Diagno., Laxmi Dental.<BR><BR>Quality Snapshot: Excellent management risk is observed at Poly Medicure, Vijaya Diagnost., Metropolis Healt, and Thyrocare Tech., while Average management risk is found at Indegene, Vimta Labs, Krsnaa Diagnost., and Laxmi Dental. Below Average management risk is noted for Suven Life Scie. Good growth is seen at Suraksha Diagno. and Laxmi Dental, while Below Average growth is present in Poly Medicure, Vijaya Diagnost., Indegene, Metropolis Healt, Thyrocare Tech., Suven Life Scie., Vimta Labs, Krsnaa Diagnost., and the rest. Excellent capital structure is held by Poly Medicure, Vijaya Diagnost., Indegene, Metropolis Healt, Thyrocare Tech., Vimta Labs, Krsnaa Diagnost., and Laxmi Dental, while Below Average capital structure is noted for Suven Life Scie.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Thyrocare Tech. at 61.22%, while Laxmi Dental has the lowest at -48.44%. Nephrocare Healt's 1-year return is not available for comparison. Additionally, the peers with negative six-month returns include Krsnaa Diagnost., Suraksha Diagno., and Laxmi Dental.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

With ROE of 6.9, it has a Very Expensive valuation with a 6.2 Price to Book Value

  • Over the past year, while the stock has generated a return of NA, its profits have risen by 15%
2

Falling Participation by Institutional Investors

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Healthcare Services

stock-summary
Market cap

INR 6,923 Cr (Small Cap)

stock-summary
P/E

89.00

stock-summary
Industry P/E

69

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.31

stock-summary
Return on Equity

6.88%

stock-summary
Price to Book

6.23

Revenue and Profits:
Net Sales:
266 Cr
(Quarterly Results - Mar 2026)
Net Profit:
30 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
27.12%
0%
27.12%
6 Months
30.88%
0%
30.88%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Nephrocare Healt for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Nephrocare Health Services Ltd Gains 1.23%: 3 Key Factors Driving the Week

Announcements stock-summary

Announcement under Regulation 30 (LODR)-Trading Plan under SEBI (PIT) Regulations 2015

05-Aug-2026 | Source : BSE

Please find enclosed the Trading Plans dated August 05 2026 received from Designated Persons of the company and same have been approved by the compliance officer.

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

24-Jul-2026 | Source : BSE

Pursuant to Regulation 30 of the SEBI Listing Regulations we hereby inform you that the Company has scheduled an Investor Result Conference Call on Wednesday 12th August 2026 at 10:00 A.M IST to discuss the Unaudited Financial Results of the Company for the quarter ended 30th June 2026. A copy of the invitation is also attached for your information

Board Meeting Intimation for The Company Has Informed BSE That The Meeting Of The Board Of Directors Is Scheduled On 11/08/2026 Inter Alia To Consider And Approve The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter E

24-Jul-2026 | Source : BSE

Nephrocare Health Services Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11-08-2026 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2026.

Corporate Actions stock-summary

stock-summary
BOARD MEETING

11 Aug 2026

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
0
EBIT to Interest (avg)
3.39
Debt to EBITDA (avg)
0.35
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.84
Tax Ratio
20.52%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
17.83%
ROCE (avg)
17.70%
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
89
Industry P/E
69
Price to Book Value
6.25
EV to EBIT
48.62
EV to EBITDA
29.20
EV to Capital Employed
8.61
EV to Sales
6.63
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
17.70%
ROE (Latest)
6.88%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
RSI
No Signal
Bollinger Bands
Bullish
KST
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 9 Schemes (3.2%)

FIIs

Held by 17 FIIs (8.78%)

Promoter with highest holding

Edoras Investment Holdings Pte Ltd (28.3%)

Highest Public shareholder

Investcorp India Investments Holding Limited (6.29%)

Individual Investors Holdings

5.7%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 2.28% vs 3.04% in Dec 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 28.88% vs 126.07% in Dec 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "164.33",
          "val2": "160.66",
          "chgp": "2.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "22.08",
          "val2": "22.86",
          "chgp": "-3.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.27",
          "val2": "3.96",
          "chgp": "-67.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "10.89",
          "val2": "8.45",
          "chgp": "28.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "13.44%",
          "val2": "14.23%",
          "chgp": "-0.79%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "alert": "No Half Yearly Results declared by Nephrocare Healt"
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Nephrocare Healt"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "629.74",
          "val2": "543.60",
          "chgp": "15.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "88.16",
          "val2": "94.89",
          "chgp": "-7.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "49.76",
          "val2": "14.30",
          "chgp": "247.97%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-8.06",
          "val2": "34.24",
          "chgp": "-123.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "14.00%",
          "val2": "17.46%",
          "chgp": "-3.46%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Mar'26 - QoQstock-summary

Mar'26
Dec'25
Change(%)
Net Sales
164.33
160.66
2.28%
Operating Profit (PBDIT) excl Other Income
22.08
22.86
-3.41%
Interest
1.27
3.96
-67.93%
Exceptional Items
0.00
0.00
Standalone Net Profit
10.89
8.45
28.88%
Operating Profit Margin (Excl OI)
13.44%
14.23%
-0.79%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2026 is 2.28% vs 3.04% in Dec 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is 28.88% vs 126.07% in Dec 2025

Annual Results Snapshot (Standalone) - Mar'26stock-summary

Mar'26
Mar'25
Change(%)
Net Sales
629.74
543.60
15.85%
Operating Profit (PBDIT) excl Other Income
88.16
94.89
-7.09%
Interest
49.76
14.30
247.97%
Exceptional Items
0.00
0.00
Standalone Net Profit
-8.06
34.24
-123.54%
Operating Profit Margin (Excl OI)
14.00%
17.46%
-3.46%
Values in Rs Cr.
Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

stock-summaryCompany CV
About Nephrocare Health Services Ltd stock-summary
stock-summary
Nephrocare Health Services Ltd
Small Cap
Healthcare Services
Nephrocare Health Services Limited was incorporated as "Nephrocare Health Services Private Limited", a private limited company at Hyderabad with a certificate of incorporation issued by the Assistant Registrar of Companies, Andhra Pradesh on December 18, 2009.
Company Coordinates stock-summary
Icon
No Company Details Available